Fennec Pharmaceuticals (FRX.TO) said on Friday that new research evaluating Pedmark (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared at the 2026 American Society of Clinical Oncology Annual Meeting program in Chicago from May 29 to June 2.
Pedmark is currently approved for pediatric patients one month of age and older with localized, non-metastatic solid tumors. The studies expand understanding of the clinical utility of Pedmark in adolescent and young adult (AYA) and adult populations, and offers evidence that the administration of Pedmark six hours after cisplatin can be safe and easily integrated into patient care. Pedmark also does not compromise cisplatin's antitumour activity, the company added.
"Collectively, these studies represent an important step forward in addressing a critical unmet need and highlight the potential for Pedmark to meaningfully impact patient care more broadly. At the same time, significant gaps and opportunities remain. Adolescent and young adult as well as adult patients continue to face a similar burden, yet prospective data in these populations are still emerging," said Pierre Sayad, chief medical officer of Fennec.
"The research being shared at the American Society of Clinical Oncology Annual Meeting reflects Fennec's ongoing commitment to expanding the evidence base supporting use and integration of Pedmark to prevent cisplatin induced ototoxicity in additional patient populations and tumor types," Sayad added.
Fennec Pharmaceutical shares closed up $0.10 to $13.60 on Thursday on the Toronto Stock Exchange.